Coherus Oncology Inc.
ABOUT US
Coherus Oncology is focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies that potentially extend patient survival across tumor types. Every member of the Coherus Oncology team is dedicated, motivated, and passionate about improving patient care. Our colleagues are experts in immunology, analytical and process sciences, biologic process development, manufacturing and supply chain management, deeply experienced in clinical development and regulatory affairs, and have proven commercial and marketing capabilities.
333 Twin Dolphin Drive, Ste 600
Redwood City, CA 94065
coherus.com
PRIMARY CONTACTS
Bill Asbury
Senior Director, National Accounts
(973) 970-4933
basbury@coherus.com
Shardae Young
Senior Medical Science Liaison
(708) 831-1750
syoung@coherus.com
PRODUCTS OR SERVICES
Coherus Oncology is building a leading oncology company backed by in-house expertise and an established commercial infrastructure. We currently have one FDA-approved cancer medicine, LOQTORZI® (toripalimab-tpzi), and we are passionate about developing and commercializing our pipeline of novel, next-generation immuno-oncology treatments that can extend patient survival across tumor types.
The foundation of our immuno-oncology franchise is built upon LOQTORZI, a next-generation PD-1 inhibitor. LOQTORZI is the only available FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC), and it is in development for the treatment of additional tumor types with the goal of being the PD-1/ICI backbone of future treatment combinations that may extend survival for patients.